MedTrace Logo

Antisense Oligonucleotide for Spinal Muscular Atrophy

NCT05187260 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-01-26

No results posted yet for this study

Summary

This is a longitudinal, multiple-center, observational study of patients genetically confirmed chromosome 5q SMA to monitor the efficacy, safety, tolerability of SPINRAZA® (nusinersen) for up to 24 months.

Conditions

Interventions

DRUG

Nusinersen

SPINRAZA® (nusinersen) prescribed as part of standard of care

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • First Affiliated Hospital of Fujian Medical University

    lead OTHER

Principal Investigators

  • Wan-Jin Chen · First Affiliated Hospital Fujian Medical University

Eligibility

Min Age
1 Week
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05187260 on ClinicalTrials.gov